Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

276 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.
Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T, Zimman R, Drake L, Riedel ER, Hedvat CV, Teruya-Feldstein J, Filippa DA, Fleisher M, Nimer SD, Comenzo RL. Hassoun H, et al. Among authors: dhodapkar m. Br J Haematol. 2006 Jan;132(2):155-61. doi: 10.1111/j.1365-2141.2005.05848.x. Br J Haematol. 2006. PMID: 16398649 Free article. Clinical Trial.
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.
Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J, Shaughnessy JD, Jagannath S, Bolejack V, Gurley J, Hoering A, Vesole D, Desikan R, Siegel D, Mehta J, Singhal S, Munshi NC, Dhodapkar M, Jenkins B, Attal M, Harousseau JL, Crowley J. Barlogie B, et al. Among authors: dhodapkar m. Br J Haematol. 2006 Oct;135(2):158-64. doi: 10.1111/j.1365-2141.2006.06271.x. Epub 2006 Aug 25. Br J Haematol. 2006. PMID: 16939489 Free article. Clinical Trial.
Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.
Jagannath S, Laubach J, Wong E, Stockerl-Goldstein K, Rosenbaum C, Dhodapkar M, Jou YM, Lynch M, Robbins M, Shelat S, Anderson KC, Richardson PG. Jagannath S, et al. Among authors: dhodapkar m. Br J Haematol. 2018 Aug;182(4):495-503. doi: 10.1111/bjh.15384. Epub 2018 May 29. Br J Haematol. 2018. PMID: 29808907 Free PMC article. Clinical Trial.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.
Shah N, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, Krishnan A, Lin Y, Manasanch E, Munshi NC, Nooka AK, Rapoport AP, Smith EL, Vij R, Dhodapkar M. Shah N, et al. Among authors: dhodapkar m. J Immunother Cancer. 2020 Jul;8(2):e000734. doi: 10.1136/jitc-2020-000734. J Immunother Cancer. 2020. PMID: 32661116 Free PMC article. Clinical Trial.
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Usmani SZ, Hoering A, Ailawadhi S, Sexton R, Lipe B, Hita SF, Valent J, Rosenzweig M, Zonder JA, Dhodapkar M, Callander N, Zimmerman T, Voorhees PM, Durie B, Rajkumar SV, Richardson PG, Orlowski RZ; SWOG1211 Trial Investigators. Usmani SZ, et al. Among authors: dhodapkar m. Lancet Haematol. 2021 Jan;8(1):e45-e54. doi: 10.1016/S2352-3026(20)30354-9. Epub 2020 Dec 22. Lancet Haematol. 2021. PMID: 33357482 Free PMC article. Clinical Trial.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Clinical Trial.
Anti-myeloma activity of pamidronate in vivo.
Dhodapkar MV, Singh J, Mehta J, Fassas A, Desikan KR, Perlman M, Munshi NC, Barlogie B. Dhodapkar MV, et al. Br J Haematol. 1998 Nov;103(2):530-2. doi: 10.1046/j.1365-2141.1998.00976.x. Br J Haematol. 1998. PMID: 9827929 Free article.
Antitumor activity of thalidomide in refractory multiple myeloma.
Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B. Singhal S, et al. Among authors: dhodapkar m. N Engl J Med. 1999 Nov 18;341(21):1565-71. doi: 10.1056/NEJM199911183412102. N Engl J Med. 1999. PMID: 10564685 Free article. Clinical Trial.
276 results